Stohl W
University of Southern California School of Medicine, USA.
Arthritis Rheum. 1995 Apr;38(4):506-16. doi: 10.1002/art.1780380408.
To determine whether impaired generation of polyclonal T cell cytolytic activity is over-represented in systemic lupus erythematosus (SLE) compared with other rheumatologic diseases and whether such impaired generation of cytolytic activity waxes and wanes with disease activity and/or changes in medications.
Peripheral blood mononuclear cells from 84 SLE patients, 55 rheumatologic disease (RD) controls, and 44 normal subjects were stimulated with anti-CD3 monoclonal antibody, maintained in interleukin-2, and assayed for cytolytic activity against 51Cr-labeled Daudi target cells.
Generation of cytolytic activity was significantly lower in SLE patients than in either RD or normal controls. Abnormal cytolytic responses in SLE could not be attributed to the patient's sex, race, age, disease activity, or antirheumatic medications (including corticosteroids and cytotoxics), although both SLE and RD patients taking azathioprine (AZA) manifested lower responses than did corresponding patients not taking AZA. Abnormal cytolytic activity reflected, in large measure, impaired cytolytic activity of CD8+ T cells. No significant difference in the generation of cytolytic activity between RD and normal controls was detected.
Impaired generation of polyclonal T cell cytolytic activity may be a predisposing factor in the development of SLE.
确定与其他风湿性疾病相比,系统性红斑狼疮(SLE)患者多克隆T细胞溶细胞活性生成受损的情况是否更为突出,以及这种溶细胞活性生成受损是否随疾病活动和/或药物变化而波动。
用抗CD3单克隆抗体刺激84例SLE患者、55例风湿性疾病(RD)对照者和44例正常受试者的外周血单个核细胞,在白细胞介素-2中培养,并检测其对51Cr标记的Daudi靶细胞的溶细胞活性。
SLE患者的溶细胞活性生成显著低于RD患者或正常对照者。SLE患者异常的溶细胞反应不能归因于患者的性别、种族、年龄、疾病活动或抗风湿药物(包括皮质类固醇和细胞毒性药物),尽管服用硫唑嘌呤(AZA)的SLE和RD患者的反应均低于未服用AZA的相应患者。异常的溶细胞活性在很大程度上反映了CD8 + T细胞溶细胞活性受损。未检测到RD患者和正常对照者在溶细胞活性生成方面的显著差异。
多克隆T细胞溶细胞活性生成受损可能是SLE发病的一个易感因素。